HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Lexicon Pharmaceuticals (NASDAQ:LXRX) and maintained a $10 price target.
June 24, 2024 | 10:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Lexicon Pharmaceuticals and maintained a $10 price target.
The reiteration of a Buy rating and the maintenance of a $10 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100